Literature summary for 3.4.14.5 extracted from

Serra, D.; He, Y.L.; Bullock, J.; Riviere, G.J.; Balez, S.; Schwartz, S.; Wang, Y.; Ligueros-Saylan, M.; Jarugula, V.; Dole, W.P.
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes (2008), Int. J. Clin. Pharmacol. Ther., 46, 349-364.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	coadministration of DPP-4 inhibitor vildagliptin with either glyburide or pioglitazone in patients with diabetes type 2 improves postprandial glycemic control	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
vildagliptin	more than 90% inhibition within 30 min of administration of vildagliptin and glyburide, while glyburide alone has no effect on DPP-4 activity	Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
glucagon-like peptide 1 + H2O	Homo sapiens	-	?	-	?

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
blood plasma	-	Homo sapiens	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
glucagon-like peptide 1 + H2O	-	Homo sapiens	?	-	?
Gly-L-Pro-7-amido-4-methylcoumarin + H2O	-	Homo sapiens	Gly-L-Pro + 7-amino-4-methylcoumarin	-	?

Synonyms

Synonyms	Comment	Organism
dipeptidyl peptidase IV	-	Homo sapiens
DPP-4	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)